Show Summary Details
Page of

Treatment-Resistant Posttraumatic Stress Disorder 

Treatment-Resistant Posttraumatic Stress Disorder
Treatment-Resistant Posttraumatic Stress Disorder

Kerry-Ann Louw

and Dan J. Stein

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 12 November 2018

Posttraumatic stress disorder (PTSD) is a prevalent, disabling condition with considerable comorbidity and morbidity. There is growing evidence supporting the efficacy and safety of pharmacotherapeutic and psychotherapeutic interventions for PTSD. However, a significant proportion of individuals with PTSD do not respond to first-line treatments. Strategies for managing treatment-resistant PTSD include switching to a different treatment, increasing dose and duration of pharmacotherapy, augmenting pharmacotherapy with a drug from a different class, or combining pharmacotherapy with psychotherapy. This chapter reviews the current evidence for these various strategies as well as novel approaches targeting the disrupted neuronal circuitry and molecular mechanisms hypothesized to underlie PTSD.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.